Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Gains from Sales and Divestitures (2018 - 2025)

Historic Gains from Sales and Divestitures for Aytu Biopharma (AYTU) over the last 8 years, with Q4 2025 value amounting to $81119.0.

  • Aytu Biopharma's Gains from Sales and Divestitures rose 93296.83% to $81119.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $81119.0, marking a year-over-year increase of 93296.83%. This contributed to the annual value of $11193.0 for FY2025, which is 5690.19% down from last year.
  • Aytu Biopharma's Gains from Sales and Divestitures amounted to $81119.0 in Q4 2025, which was up 93296.83% from $1618.0 recorded in Q3 2025.
  • Aytu Biopharma's Gains from Sales and Divestitures' 5-year high stood at $642696.0 during Q2 2022, with a 5-year trough of $1618.0 in Q3 2025.
  • For the 5-year period, Aytu Biopharma's Gains from Sales and Divestitures averaged around $76132.8, with its median value being $28352.0 (2022).
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 9339.75% in 2023, then skyrocketed by 93296.83% in 2025.
  • Over the past 5 years, Aytu Biopharma's Gains from Sales and Divestitures (Quarter) stood at $90836.0 in 2021, then tumbled by 66.17% to $30733.0 in 2022, then tumbled by 60.34% to $12189.0 in 2023, then crashed by 35.57% to $7853.0 in 2024, then skyrocketed by 932.97% to $81119.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $81119.0 for Q4 2025, versus $1618.0 for Q3 2025 and $11193.0 for Q2 2025.